Edit

ExpreS2ion Biotechnologies

http://www.expres2ionbio.com/

ExpreS2ion Biotechnologies is a clinical-stage DK based biotech company specialised in the development of new vaccines and immunotherapy products. The company has a discovery platform built around a proprietary recombinant expression system, ExpreS2 TM, developed especially for fast and efficient development and production of complex proteins required for innovative new vaccines, immunotherapy and diagnostics. The system also includes functionally modified glycosylation variants.

The development pipeline includes two different malaria vaccine projects in clinical Phase II (blood-stage malaria) and clinical Phase I (pregnancy-associated malaria), respectively. For the clinical Phase I/II-stage COVID-19 vaccine, ABNCoV2, the Company employs a novel plug-&-play capsid virus-like particle (cVLP) platform, that offers competitive advantages in terms of long-term efficacy, safety, stability, and costing. The cVLP and ExpreS2 TM platforms are also basis for a proprietary HER2-cVLP breast cancer vaccine, ES2B-C001, which has proven preclinical proof of concept. Furthermore, ExpreS2ion also develops novel influenza vaccines currently in preclinical development.

Since founded in 2010, ExpreS2ion has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with a high number of leading research institutions, biotech and pharma companies, demonstrating superior efficiency and success rates. The cVLP platform resides in its joint venture partner AdaptVac that was founded in 2017.

ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary and operational unit of ExpreS2ion Biotech Holding AB, listed on Nasdaq first North, Stockholm (Ticker: EXPRS2).